USA Today - 03.10.2019

2A z THURSDAY, OCTOBER 3, 2019 z USA TODAY E2 NEWS

“The White House’s flagrant disre-
gard of multiple voluntary requests for
documents – combined with stark and
urgent warnings from the Inspector
General (of the intelligence community)
about the gravity of these allegations –
have left us with no choice but to issue
this subpoena,” Cummings wrote in a
memo to committee members that was
released along with a draft subpoena.
Trump attacked House Intelligence
Committee Chairman Adam Schiff and
House Speaker Nancy Pelosi when
asked Wednesday whether he’d comply.
“I always cooperate. This is a hoax,”
Trump said in an afternoon news con-
ference with Finland’s president. “But
we’ll work together with Shifty Schiff
and Pelosi and all of them, and we’ll see
what happens.”
Earlier, Trump live-tweeted a news
conference by Pelosi and Schiffsoon af-
ter the draft subpoena was released.
Trump challenged Pelosi’s stated

desire to work on issues such as trade

and prescription drug prices, saying

Democrats are too obsessed with im-

peachment.

Pelosi is “incapable” of working on

other issues, Trump tweeted. “It is just

camouflage for trying to win an election

through impeachment. The Do Nothing

Democrats are stuck in mud!”

Pelosi said Democrats can work with

the administration on infrastructure,

drug costs and other issues.

“Clean government?” she added.

“That’s more of a challenge.”

Tuesday, Secretary of State Mike

Pompeo pushed to delay testimony by

five State Department officials whom

House Democrats asked to depose. He

accused Democrats of trying to “intimi-

date” and “bully” career professionals in

their quest to impeach Trump.

Wednesday, Pompeo acknowledged

that he listened in on the controversial

phone call between Trump and

Ukraine’s leader, Volodymyr Zelensky, a

conversation that sparked the House

Democrats’ impeachment inquiry.

That call prompted a whistleblower

to file an anonymous complaint alleging

that Trump was “using the power of his

office to solicit interference from a for-

eign country in the 2020 U.S. election.”

Rudy Giuliani, Trump’s personal at-

torney, publicly acknowledged that he

pressed Ukrainian government officials

to open an investigation into former

Vice President Joe Biden, a leading can-

didate for the 2020 Democratic presi-

dential nomination. He said he contact-

ed Ukrainian officials at the direction of

the State Department and he briefed

U.S. diplomats on his conversations.

House Democrats opened the im-

peachment inquiry last week, focused

on examining the “extent to which

President Trump may have jeopardized

national security” by pressing Ukraine

to investigate Biden and by withholding

military assistance to help Ukraine

counter Russian aggression.

“We’re not fooling around here,”

Schiff said Wednesday. “It’s hard to

imagine a more corrupt course of con-

duct.”

Schiffrepeated a warning Democrats

have made that attempts by the White

House to block the investigation will be

considered evidence of obstruction and

will imply that the allegations being in-

vestigated “are, in fact, correct.”

If the White House isn’t forthcoming,

Schiffsaid, Democrats “will have to de-

cide whether to litigate or how to liti-

gate.”

“We don’t want this to drag on

months and months and months, which

appears to be the administration’s strat-

egy,” he said.

Democrats subpoenaed Pompeo for

documents last week and issued a sub-

poena to Giuliani on Monday.

Pelosi “hands out subpoenas like

they’re cookies,” Trump said. “ ‘You

want a subpoena? Here you go. Take

them.’ Like they’re cookies.”

Cummings’ memo to other members

of the committee said there’s no time for

the panel to vote on the subpoena

“without causing undue delay to the in-

vestigation” because lawmakers are in a

two-week recess. Instead, Cummings

said, the subpoena will be issued under

the rules of the House in consultation

with the leaders of the House foreign af-

fairs and intelligence committees,

which also are investigating Trump.

Contributing: Deirdre Shesgreen

White House

Continued from Page 1A

Americans by a 45%-38% plurality
now support a vote by the House of Rep-
resentatives to impeach President
Trump, a new USA TODAY/Ipsos Poll
finds, as allegations continue to swirl
around an embattled White House.
By a similar margin, 44%-35%, those
surveyed say the Senate, which would
then be charged with holding a trial of
the president, should convict Trump and
remove him from office.
The survey of 1,006 adults, taken
Tuesday and Wednesday, underscores
the perilous situation the president finds
himself in as House committees sub-
poena documents and prepare to hear
testimony into accusations that Trump
pressured the president of Ukraine to in-
vestigate a political rival, then tried to

hide the account of their phone conver-

sation.

A USA TODAY/Suffolk University Poll

taken in June found Americans opposing

impeachment by nearly 2-1, 61%-32%.

But several national surveys have shown

a jump in support over the past 10 days,

since the latest allegations emerged

about Ukraine and House Speaker Nan-

cy Pelosi announced she was launching a

formal impeachment inquiry.

The question of impeachment opens

a huge partisan divide, to be sure.

Among Democrats, 74% of those sur-

veyed in the new USA TODAY/Ipsos poll

support impeachment; just 17% of Re-

publicans support it. Independents are

split down the middle, 37%-37%.

Even among Republicans, however,

30% say the president asking Ukraine to

look into the behavior of former Vice

President Joe Biden and his son Hunter

would be an abuse of power. And 80% of

Republicans – a higher number than

among Democrats or independents – say

the president is subject to all laws, just

like any other citizen.

One more warning sign for Trump:

Nearly two-thirds of Republicans say

there isn’t enough reliable information to

decide whether he should be impeached.

That leaves open the possibility that dra-

matic disclosures and evidence could

convince some in Trump’s own party

that impeachment is warranted.

Democrats are more likely to say they

already know enough; just 15% say there

isn’t enough evidence so far.

The survey includes some cautionary

findings as well for Biden, the Democrat-

ic front-runner to challenge Trump next

year. By 2-1, 42%-21%, those polled say

there are valid reasons to look at the be-

havior of Joe and Hunter Biden in Uk-

raine. Joe Biden was the Obama admini-

stration’s point person on Ukraine; his

son pursued lucrative business arrange-

ments there.

There has been no evidence of wrong-

doing by either of them, though Trump

on Wednesday accused them of being

corrupt.

The poll found that more than six in 10

Republicans and Democrats agreed that

the children of senior officials should be

prohibited from benefiting from their

family relationships. While such con-

nections often are not illegal, the percep-

tion of self-dealing and conflicts of inter-

est have long fueled voter distrust of gov-

ernment and its leaders.

Views were mixed about the whistle-

blower who originally reported concerns

about Trump’s telephone call with the

Ukrainian president. Seventy-one per-

cent of Democrats call him or her “a pa-

triot;” just 10% call him or her “a traitor,” a

label that Trump has used. But the presi-

dent hasn’t yet persuaded a majority of

members of his own party that the de-

scription fits.

Among Republicans, 36% call the

whistleblower “a traitor,” but 21% say he

or she is a patriot. The largest number,

43%, say they don’t know

The online poll has a credibility inter-

val of plus or minus 3.5 percentage

points.

New poll suggests Trump on shaky ground

Susan Page
USA TODAY

More voters now support

a vote for impeachment

ADVERTISEMENT

Good News for Americans,Bad News for Pain Drugs

Millions areexpected to benefit fromanew technology that couldrelieve ye arsofs everejoint discomfort;

reprograms the body to block slowburning inflammation instead of creating it

THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE OR PREVENT ANY DISEASE. RESULTS MAYVARY.

Veraflex producers are making these new pills as fast as possible

to meet the growing and increasing demand.

Severa lofthe major drug

companies behind popular pain

relievers maytakeafinancial hit as

manufacturing ofanew pill is now

complete.

Usinganew technology,the

pill could be safer and more

effectivethan manystorebought

brands.

The pill,VeraFlex,was devel-

oped in Mayofthis year by a

private companyinSeattle.

Functioning primarily as an im-

mune modulator,the pill targets

the body’simmunesystem which

can decrease pain in the body.

The Science BehindRelief

Research shows that the joint

stiffness,soreness and discom-

fort associated with arthritis is

causedby inflammation which

attacks healthycartilage and

protectivetissue.

And according to leading med-

ical scientists,this inflammation

is causedby twoinflammatory

enzymesreleasedby the body’s

immunesystem.

Remarkably,the activeingre-

dients inVeraFlexhelp to block

the production of both these

enzymes,resulting inadramatic

decreasing in swelling, inflam-

mation, and discomfort.

Right now, the leadingover-

the-counter pills areonly able to

block one of these enzymes!

It’swhy so manysufferersfail

to everfind relief.

YearsofDiscomfort

Relievedin5Days

“VeraFlexuserscan generally

expect moreflexibility in three

days...their joint pain alleviated

in fivedays...and in just seven

days, atremendous improve-

ment in overall joint function

that mayhelp them move like

theydid yearsprior”explains Dr.

Liza Leal, developer and spokes-

person forVeraFlex.

8patents that spread from the

US into Canada. And aswould

one guess,it’sbacked by an

enormous amount of research,

including twopatient clinical

trials.

In the first, 60 participants with

rheumatoid arthritis and/or os-

teoarthritiswere randomly placed

into four groups.

Twogroups weregiven the pat-

ented ingredient inVeraFlex,one

wasgiven the drug Celecoxib,

and the last groupaplacebo. The

resultsweremonitored at30,60,

and 90 days.

The data collectedby re search-

erswas stunning.

The groups taking theVeraFlex

ingredient sawstaggering

improvements in arthritissymp-

toms such as flexibility,discom-

fort and function.

And evenmoreastonishing

theyexperienced adramatic

reduction in painby the 30-day

mark thatwasevenbetter than

Celecoxib,apowerful drug!

Asecond studywasconducted

to ensurethe datawasaccurate

and again theresults participants

experienced taking theVeraFlex

compound blewaway researchers.

This time it beat out the drug

Naproxen. Shockingly,both

men andwomenexperienced a

reduction in joint stiffness two

days faster than when using

Naproxen.

“I have to admit Iwas sur-

prised when Iread the initial

findings” explains Leal. “But

whenyoulook at the science it

just makes sense.It’sgoing to

changeeverything.”

Faster Delivery,Maximum

Absorption

VeraFlexis mainly comprised

of twopatented ingredients:

Univestin, apowerful immune

modulator which blocks the

enzymes which causeyour joints

to hurt and BiAloe,anabsorp-

tion enhancer (accelerator) that

ensures maximum potency.

Research shows that severe

joint discomfort arises when the

immune system goes haywire

and releases COXand LOXinto

your blood stream, twoenzymes

that causes tremendous swell-

ing and inflammation around

cartilage and protectivetissue.

Over time,this inflammation

overwhelms the joint and it

begins to deteriorateresulting in

adaily battle with chronic pain.

Unfortunately,modern day

pain pills areonly able block

only one of these enzymes,

resulting in marginalrelief and

continued suffering.

The Univestin in VeraFlex

is one of the only known sub-

stances which has been proven

successful in blocking both en-

zymes,resulting in phenomenal

relief from thewors tkinds of

discomfort.

The addition of BiAloe,a

unique aloevera extra, maximiz-

es the delivery of the plant based

Univestinextract toevery joint in

the body because it is provento

improve nutrient absorption for

maximumresults.

AloeVera also is provento

support the body’simmune

system which manages inflam-

mation, further supportingrelief.

HowtoClaim aFree

3-Month Supply OfVeraFlex

This is the official nationwide

release ofVeraFlex.And so, the

companyisoffering ourreaders

up to3FREE bottles with their

order.

This special give-away is avail-

able for the next 48-hoursonly.

All youhave to do is call toll free

1-800-234-7806and provide the

operator with the FreeBottle

ApprovalCode: VF350. The

companywill do therest.

Important: Due toVeraFlex’s

recent mediaexposure, and Dr.

Leal’slatest book deal, phone

lines areoften busy. If youcall

and do not immediately get

through, please be patient and

call back. Those who miss the

48-hour deadline maylose out

on this free bottle offer.

“It’sani ncredibly powerful lit-

tle pill. And with the addition of

apatented absorption enhancer,

it packs anevengreater punch.

That’swhy I’m soexcited to be

the first to sharethese results.

It’sgiving suffererstheir life

back.”

ASafer,MoreEffective

Avenue to AmazingRelief

Its widely accepted through

the medical community that

inflammatory enzymes arethe

primary cause of pain and suffer-

ing in millions of Americans.It’s

whymost prescriptions andeven

nonprescription pills aredesigned

to block them.

However, what most people

don’t knowisthat eventhe most

advanced ones can’t block both!

Andyet, that’sexactly what

VeraFlexis designed to do and

whyitworks sowell.

“Top pharma companies have

struggled to createadrug that

blocks COXand LOX; the medical

names for the twoinflammatory

enzymes in the body.Consider

the top seller Celebrex,itonly

blocks onevariation of the COX

enzyme”explains Leal.

“And that’sbecause theyhave

focused on using chemicals in-

stead of natural substances like

VeraFlex.”

“Every VeraFlex capsule

contains an ultra-high dose of a

patented plantextract which has

been clinically shown to block

both enzymes,bringingrelief to

every joint that hurts!

“The kind of relief most

people have neverexperienced.

Ioften saytwo enzymes,twice

the relief. People think I’m kid-

ding until theytry it.”

Piling on the Clinical

Research

Remarkably,the key ingredi-

ent inVeraFlexis protectedby